Newsroom | 5434 results

SAN DIEGO--(BUSINESS WIRE)--RevolutionEHR, the market-leading optometry-first operating platform, today announced the launch of RevPay, its fully embedded payments solution designed to help practices get paid effortlessly while recovering more of the revenue they earn. RevPay connects payments directly to RevolutionEHR’s AI-native platform, integrating checkout, patient records, engagement, and reporting into one intelligent workflow. By embedding payments into the platform’s intelligence engin...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025. “We enter 2026 with the momentum of our continued execution,” said Steve Mahoney, President and Chief Executive Officer of Viridian. “With the veligr...

NEW YORK--(BUSINESS WIRE)--Warby Parker Inc. (NYSE: WRBY) (“Warby Parker” or the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the fourth quarter and full year ended December 31, 2025. Highlights Delivered revenue growth of 13.0% for full year 2025 and 11.2% for the fourth quarter. Drove Active Customer growth of 7.0%, and Average Revenue per Customer of $324, up 5.7% year over year. Achieved first full year of positive net inc...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that more than 4 million Implantable Collamer® Lenses (ICLs) have been sold worldwide, marking a milestone in the global shift away from laser-based refractive surgery. This achievement underscores the growing global preference for lens-based solutions in refractive vision correction as...

GENEVA--(BUSINESS WIRE)--Alcon Delivers Strong Fourth-Quarter 2025 Topline Growth as New Product Launches Accelerate Sales...

GENEVA--(BUSINESS WIRE)--Alcon Delivers Strong Fourth-Quarter 2025 Topline Growth as New Product Launches Accelerate Sales...

DULUTH, Ga.--(BUSINESS WIRE)--National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today announced that the Company will participate in the following upcoming conferences: Citi 2026 Global Consumer & Retail Conference Date: March 9, 2026 Format: Fireside chat at 1:45pm ET and investor meetings BofA 2026 Consumer & Retail Conference Date: March 10, 2026 Format: Investor meetings A live webcast of the fireside chat at the Citi 2026 Global Consumer & Retail...

STAMFORD, Conn--(BUSINESS WIRE)--TECLens, Inc., a clinical-stage ophthalmic medical device company, announced today the treatment of the initial patient for its first-in-human clinical trial evaluating the company's groundbreaking quantitative corneal crosslinking (qCXL™) technology for non-invasive refractive vision correction. The study marks a significant milestone in the development of the first vision correction platform designed to strengthen rather than compromise corneal integrity. The...

WOODBRIDGE, Conn.--(BUSINESS WIRE)--LambdaVision, an innovative biotech company developing a protein-based artificial retina to help patients regain sight lost to retinal degenerative diseases, is advancing its commercialization efforts by pre-booking commercial space in low-Earth orbit (LEO) through partnerships with Starlab Space LLC, a joint venture led by Voyager Technologies. This strategic agreement supports LambdaVision’s plan to scale manufacturing of its protein-based artificial retina...

HOUSTON--(BUSINESS WIRE)--Starlab Space LLC, the commercial space station developer expanding access to low Earth orbit research, today announced a reservation agreement with LambdaVision, a biotechnology company developing a protein-based artificial retina designed to restore vision for patients with retinal degenerative diseases. The reservation agreement supports LambdaVision’s transition from research to long-term, scalable biomedical production in space and ensures its continued access to...